Body weight is regulated by complex neurohormonal interactions between endocrine signals of long-term adiposity (e.g., leptin, a hypothalamic signal) and short-term satiety (e.g., amylin, a hindbrain signal). Ultimately, active weight loss and maintaining a weight-reduced state engage counter-regulatory responses that render monotherapy-based diet drugs relatively ineffective. This presentation will highlight potential strategies for overcoming these responses with biologic combinations. As an example of synergy, translational research findings from the development of pramlintide (an amylin receptor agonist) and recombinant leptin  as a weight-loss combination will be highlighted. Pharmacologic, mechanistic and practical considerations and challenges encountered during development will be discussed.

"Weighty matters": Fixed dose combinations for obesity

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.